US FDA reinforces mandatory adverse event reporting for BioCryst's IV peramivir
30 December 2009
Nancy Faigen
In an alert, the
US FDA has reminded healthcare providers that they are required to report adverse effects, irrespective of causality, with emergency use of
BioCryst Pharamceuticals' antiviral IV peramivir in hospitalised H1N1 patients.
The alert, posted on the agency's website, outlines the...
Please Login to read the full article.
30 December 2009
Nancy Faigen
The alert, posted on the agency's website, outlines the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- BARDA rescues BioCryst with additional $55 million for peramivir
- 'Salt bridge' identified as promising target for novel flu drugs
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- US Capitol Capsule: Will sequestration be a better outcome for biopharma?
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
